OBJECTIVE: To assess the quality of life (QOL) with rivaroxaban in patients with non-valvular atrial fibrilation (NVAF) related to therapeutic compliance. METHODS: Prospective, longitudinal, multicenter study was developed in 160 Spanish primary or specialized care centers. We included 412 patients treated with rivaroxaban, prescribed for stroke prevention. Three visits were conducted: baseline, 6 and 12 months. Compliance was measured by electronic monitoring systems. QOL was measured by a specific questionnaire. We calculated the percentage of compliance means, the percentage of daily compliers and the score of QOL. RESULTS: Three hundred and seventy patients finished the study (mean age 75.19 SD: 7.5 years). Daily compliance was 83.5% (CI 78.53-88.57%) (n = 309) and 80% (CI 74.65-85.35%) at 6 and 12 months, respectively. Average QOL rating was 112.85 (SD 29.31) in non-compliant and 111.80 (SD 29.31) in the compliant group (p = Not significant), and after 12 months of 124.67 (SD 30.78) and 83.47 (SD 26.44), respectively (p < 0.0001), with a decrease in the score compliers (p < 0.01) and an increase in non-compliant group (p < 0.05). A higher number of drugs consumed, as well as the number of diseases/conditions suffered, the older age of the patients and having been previously treated with VKA were associated with a higher overall score (worse QOL). CONCLUSIONS: QOL in NVAF patients treated with rivaroxaban improved significantly over the study group at the expense of compliers. A worse QOL was associated with pluripathology, polymedication, older patients and previous treatment with VKA.
OBJECTIVE: To assess the quality of life (QOL) with rivaroxaban in patients with non-valvular atrial fibrilation (NVAF) related to therapeutic compliance. METHODS: Prospective, longitudinal, multicenter study was developed in 160 Spanish primary or specialized care centers. We included 412 patients treated with rivaroxaban, prescribed for stroke prevention. Three visits were conducted: baseline, 6 and 12 months. Compliance was measured by electronic monitoring systems. QOL was measured by a specific questionnaire. We calculated the percentage of compliance means, the percentage of daily compliers and the score of QOL. RESULTS: Three hundred and seventy patients finished the study (mean age 75.19 SD: 7.5 years). Daily compliance was 83.5% (CI 78.53-88.57%) (n = 309) and 80% (CI 74.65-85.35%) at 6 and 12 months, respectively. Average QOL rating was 112.85 (SD 29.31) in non-compliant and 111.80 (SD 29.31) in the compliant group (p = Not significant), and after 12 months of 124.67 (SD 30.78) and 83.47 (SD 26.44), respectively (p < 0.0001), with a decrease in the score compliers (p < 0.01) and an increase in non-compliant group (p < 0.05). A higher number of drugs consumed, as well as the number of diseases/conditions suffered, the older age of the patients and having been previously treated with VKA were associated with a higher overall score (worse QOL). CONCLUSIONS: QOL in NVAF patients treated with rivaroxaban improved significantly over the study group at the expense of compliers. A worse QOL was associated with pluripathology, polymedication, older patients and previous treatment with VKA.
Authors: James V Freeman; DaJuanicia N Simon; Alan S Go; John Spertus; Gregg C Fonarow; Bernard J Gersh; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Laine E Thomas; Paul Chang; Eric D Peterson; Jonathan P Piccini Journal: Circ Cardiovasc Qual Outcomes Date: 2015-06-09
Authors: M E Cromheecke; M Levi; L P Colly; B J de Mol; M H Prins; B A Hutten; R Mak; K C Keyzers; H R Büller Journal: Lancet Date: 2000-07-08 Impact factor: 79.321
Authors: R Sánchez González; M Yanes Baonza; A Cabrera Majada; J M Ferrer García-Borrás; R Alvarez Nido; E Barrera Linares Journal: Aten Primaria Date: 2004-10-31 Impact factor: 1.137
Authors: Geisa de Queiroz Almeida; Lúcia de A C B Noblat; Luiz Carlos Santana Passos; Harrison Floriano do Nascimento Journal: Health Qual Life Outcomes Date: 2011-10-25 Impact factor: 3.186
Authors: A John Camm; Pierre Amarenco; Sylvia Haas; Susanne Hess; Paulus Kirchhof; Silvia Kuhls; Martin van Eickels; Alexander G G Turpie Journal: Eur Heart J Date: 2015-09-01 Impact factor: 29.983
Authors: José Felipe Varona; José Miguel Seguí-Ripoll; Cristina Lozano-Duran; Luis Miguel Cuadrado-Gómez; Juan Bautista Montagud-Moncho; Antonio Ramos-Guerrero; José Carlos Mirete-Ferrer; Esther Donado; Javier García-Alegría Journal: Health Qual Life Outcomes Date: 2020-12-11 Impact factor: 3.186